“It has been a strong start to 2024 with the initiation of the DRAGON II trial and the recent closing of our $25 million registered direct offering in April 2024,” said Tom Lin, Chairman and CEO of Belite Bio. “At the annual meeting of The Association for Research in Vision and Ophthalmology (ARVO), we announced additional analysis from our completed Phase 2 trial of Tinlarebant in adolescent STGD1 supporting its potential to slow or even halt disease progression. We are encouraged by these findings and look forward to building on this momentum as we continue to evaluate the potentially life-changing impact of this therapy in our ongoing STGD1 trials, DRAGON & DRAGON II, as well as in GA through our PHOENIX trial.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
- Belite Bio participates in a webinar with Cantor Fitzgerald
- Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
- Belite Bio presents additional analysis from Phase 2 study of tinlarebant
- Belite Bio to participate on KOL Webinar to discuss STGD1, GA